# SUBSTANTIAL EQUIVALENCE DETERMINATIONDECISION SUMMARYASSAY ONLY TEMPLATE

A. 510(k) Number: k103747   
B. Purpose for Submission: New device   
C. Measurand: HDL and LDL Cholesterol   
D. Type of Test: Colorimetric enzymatic assay   
E. Applicant: SEPPIM S.A.S.

# F. Proprietary and Established Names:

1. ELITech Clinical Systems CHOLESTEROL HDL SL 2G   
2. ELITech Clinical Systems CHOLESTEROL HDL 2G CALIBRATOR   
3. ELITech Clinical Systems CHOLESTEROL LDL SL 2G   
4. ELITech Clinical Systems CHOLESTEROL LDL 2G CALIBRATOR   
5. ELITech Clinical Systems ELITROL I and ELITROL II

# G. Regulatory Information:

<table><tr><td rowspan=1 colspan=1>Product Code</td><td rowspan=1 colspan=1>Classification</td><td rowspan=1 colspan=1>Regulation Section</td><td rowspan=1 colspan=1>Panel</td></tr><tr><td rowspan=1 colspan=1>LBS</td><td rowspan=1 colspan=1>Class I, meetslimitations per21 CFR862.9(c)(4)</td><td rowspan=1 colspan=1>21 CFR 862.1475LDL &amp; VLDL Precipitation,Cholesterol Via Esterase-Oxidase, HDL</td><td rowspan=1 colspan=1>Clinical Chemistry (75)</td></tr><tr><td rowspan=1 colspan=1>JIT</td><td rowspan=1 colspan=1>Class II</td><td rowspan=1 colspan=1>21 CFR 862.1150Calibrator</td><td rowspan=1 colspan=1>Clinical Chemistry (75)</td></tr><tr><td rowspan=1 colspan=1>JJY</td><td rowspan=1 colspan=1>Class I,reserved</td><td rowspan=1 colspan=1>21 CFR 862.1660Quality Control Material</td><td rowspan=1 colspan=1>Clinical Chemistry (75)</td></tr><tr><td rowspan=1 colspan=1>MRR</td><td rowspan=1 colspan=1>Class I, meetslimitations per21 CFR</td><td rowspan=1 colspan=1>21 CFR 862.1475System, Test, Low Density,Lipoprotein</td><td rowspan=1 colspan=1>Clinical Chemistry (75)</td></tr></table>

<table><tr><td></td><td>862.9(c)(4)</td><td></td></tr></table>

# H. Intended Use:

1. Intended use(s): See Indications for use below.

2. Indication(s) for use:

The ELITech Clinical Systems CHOLESTEROL HDL SL 2G assay is intended for use with ELITech Clinical Systems CHOLESTEROL HDL 2G CALIBRATOR and ELITech Clinical Systems ELITROL I and ELITROL II on Vital Scientific Selectra/Flexor analyzers for the quantitative in vitro diagnostic determination of High Density Lipoprotein (HDL) Cholesterol in human serum and plasma. It is not intended for point of care settings. .

Lipoprotein measurements are used in the diagnosis and treatment of lipid disorders (such as diabetes mellitus), atherosclerosis, and various liver and renal diseases.

ELITech Clinical Systems CHOLESTEROL HDL 2G CALIBRATOR is a calibrator for in vitro diagnostic use in the calibration of quantitative ELITech Clinical Systems CHOLESTEROL HDL SL 2G on the Vital Scientific Selectra Junior Analyzer and the Vital Scientific Flexor Junior Analyzer.

The ELITech Clinical Systems CHOLESTEROL LDL SL 2G assay is intended for use with ELITech Clinical Systems CHOLESTEROL LDL 2G CALIBRATOR and ELITech Clinical Systems ELITROL I and ELITROL II on Vital Scientific Selectra/Flexor analyzers for the quantitative in vitro diagnostic determination of Low Density Lipoprotein (LDL) Cholesterol in human serum and plasma. It is not intended for point of care settings.

Lipoprotein measurements are used in the diagnosis and treatment of lipid disorders (such as diabetes mellitus), atherosclerosis, and various liver and renal diseases.

ELITech Clinical Systems CHOLESTEROL LDL 2G CALIBRATOR is a calibrator for in vitro diagnostic use in the calibration of quantitative ELITech Clinical Systems CHOLESTEROL LDL SL 2G on the Vital Scientific Selectra Junior Analyzer and the Vital Scientific Flexor Junior Analyzer.

ELITech Clinical Systems ELITROL I is a multi-parametric control serum for in vitro diagnostic use in accuracy control of quantitative ELITech Clinical Systems methods on the Vital Scientific Selectra Junior Analyzer and the Vital Scientific Flexor Junior Analyzer.

ELITech Clinical Systems ELITROL II is a multi-parametric control serum for in vitro diagnostic use in accuracy control of quantitative ELITech Clinical Systems methods on the Vital Scientific Selectra Junior Analyzer and the Vital Scientific Flexor Junior Analyzer.

3. Special conditions for use statement(s):

For in vitro diagnostic use only; this assay is not intended for point of care settings.

The labeling contains a statement that all human source material was tested by FDAapproved methods and found to be non-reactive for the presence of HBsAg, HCV and antibody to HIV 1/2.

4. Special instrument requirements:

All performance was evaluated on the Vital Scientific Selectra Junior Analyzer which is also trademarked as the Vital Scientific Flexor Junior Analyzer (k973628)

# I. Device Description:

1. ELITech Clinical Systems CHOLESTEROL HDL SL 2G Kit Contents:

a. Reagent R1 – 4 vials of liquid ready to use – 21 mL each vial

i. Good’s Buffer   
ii. Cholesterol Oxidase (CO bacterial)   
iii. Peroxidase (POD horseradish)   
iv. Ascorbate Oxidase (bacterial)   
v. N,N-bis(4-sulphobutyl)-m-toluidine-disodium (DBSmT)   
vi. Accelerator and preservative

b. Reagent R2 – 4 vials of liquid ready to use – 7 mL each vial

i. Good’s Buffer ii. Cholesterol Esterase (CHE bacterial) iii. 4-Amino-Antipyrine (4-AA) iv. Detergent and Preservative

2. ELITech Clinical Systems CHOLESTEROL HDL 2G CALIBRATOR Kit Contents:

a. 4 vials of Lyophilized human serum based calibrator – makes $1 \mathrm { m L }$ per vial i. Lipoprotein from the various lipoprotein classes including high density lipoprotein ii. Sodium Azide Preservative

3. ELITech Clinical Systems CHOLESTEROL LDL SL 2G Kit Contents:

a. Reagent R1 – 4 vials of liquid ready to use – 21 mL each vial i. MES Buffer (2-(N-morpholino)ethanesulfonic acid) ii. Detergent 1 iii. Cholesterol Esterase (CHE bacterial)

iv. Cholesterol Oxidase (CO bacterial) v. Peroxidase (POD horseradish) vi. 4-Amino-Antipyrine (4-AA) vii. Ascorbate Oxidase (vegetal)

b. Reagent R2 – 4 vials of liquid ready to use – 7 mL each vial

i. MES Buffer   
ii. Detergent 2   
iii. N,N-bis(4-sulphobutyl)-m-toluidine-disodium (DBSmT)

4. ELITech Clinical Systems CHOLESTEROL LDL 2G CALIBRATOR Kit Contents:

a. 4 vials of Lyophilized human serum based calibrator – makes $1 \mathrm { m L }$ per vial i. Lipoprotein from the various lipoprotein classes including low density lipoprotein ii. Sodium Azide Preservative

5. ELITech Clinical Systems ELITROL I and ELITROL II a. 10 vials of Lyophilized human serum based control – makes 5 mL per vial i. Lipoprotein from the various lipoprotein classes ii. Preservative

# J. Substantial Equivalence Information:

1. Predicate device name(s):

1. HORIBA ABX PENTRA HDL Direct CP   
2. Genzyme Ultra N-Geneous CHOLESTEROL HDL Calibrator   
3. HORIBA ABX PENTRA LDL Direct CP   
4. Genzyme Ultra N-Geneous CHOLESTEROL LDL Calibrator   
5. Roche Precinorm U / Precipath U

2. Predicate 510(k) number(s):

1. k060854   
2. k021316   
3. k060854   
4. k971573   
5. k041227

3. Comparison with predicate:

<table><tr><td colspan="1" rowspan="1">Items</td><td colspan="1" rowspan="1">ELITech Clinical SystemsCHOLESTEROL HDL SL 2G(Candidate Device)</td><td colspan="1" rowspan="1">ABX PENTRA HDL Direct CP(Predicate Device)</td></tr><tr><td colspan="3" rowspan="1">Similarity</td></tr><tr><td colspan="1" rowspan="1">Intended Use</td><td colspan="1" rowspan="1">Same</td><td colspan="1" rowspan="1">For the in vitro determination of High DensityLipoprotein Cholesterol (HDL-C) in humanserum or plasma by colorimetry.</td></tr><tr><td colspan="1" rowspan="1">Test Principle</td><td colspan="1" rowspan="1">Same</td><td colspan="1" rowspan="1">Enzymatic colorimetric test using acceleratorselective detergent</td></tr><tr><td colspan="1" rowspan="1">ReagentComposition</td><td colspan="1" rowspan="1">Same</td><td colspan="1" rowspan="1">Reagent R1:Good's BufferCholesterol OxidasePeroxidaseN,N-bis(4-sulphobutyl)-m-toluidine-disodiumAcceleratorPreservativeReagent R2:Good's BufferCholesterol Esterase4-Amino-AntipyrineDetergentPreservative</td></tr><tr><td colspan="1" rowspan="1">Reagent Form</td><td colspan="1" rowspan="1">Same</td><td colspan="1" rowspan="1">Liquid - ready to use</td></tr><tr><td colspan="1" rowspan="1">Sample Type</td><td colspan="1" rowspan="1">Same</td><td colspan="1" rowspan="1">Serum and Li-Heparin Plasma</td></tr><tr><td colspan="1" rowspan="1">Reagent Storage</td><td colspan="1" rowspan="1">Same</td><td colspan="1" rowspan="1">2-8°C away from light until expiration date</td></tr><tr><td colspan="1" rowspan="1">Expected Values</td><td colspan="1" rowspan="1">Same</td><td colspan="1" rowspan="1">According to NCEP:High Risk: &lt; 40 mg/dLLow Risk: ≥60 mg/dL</td></tr><tr><td colspan="3" rowspan="1">Difference</td></tr><tr><td colspan="1" rowspan="1">ReagentComposition</td><td colspan="1" rowspan="1">Reagent R1:Ascorbate oxidase</td><td colspan="1" rowspan="1">Reagent R2:RestrainerAscorbic Acid Oxidase</td></tr><tr><td colspan="1" rowspan="1">Instrument</td><td colspan="1" rowspan="1">SELECTRA JUNIOR</td><td colspan="1" rowspan="1">ABX PENTRA 400</td></tr><tr><td colspan="1" rowspan="1">MeasuringRange</td><td colspan="1" rowspan="1">5 - 105 mg/dL</td><td colspan="1" rowspan="1">5.4 - 151.9 mg/dL</td></tr><tr><td colspan="1" rowspan="1">Limit ofDetection</td><td colspan="1" rowspan="1">0.7 mg/dL</td><td colspan="1" rowspan="2">1.16 mg/dL</td></tr><tr><td colspan="1" rowspan="1">Limit ofQuantitation</td><td colspan="1" rowspan="1">5.0 mg/dL</td></tr><tr><td colspan="1" rowspan="1">Precision</td><td colspan="1" rowspan="1">Within-run % CV:Level 31 mg/dL = 1.4%Level 56 mg/dL = 0.7%Level 87 mg/dL = 1.4%Total % CV:Level 31 mg/dL = 3.0%Level 56 mg/dL = 2.8%Level 87 mg/dL = 3.3%</td><td colspan="1" rowspan="1">Within-run % CV:Level 27.94 mg/dL = 1.32%Level 35.82 mg/dL = 1.29%Level 48.59 mg/dL = 1.91%Level 81.72 mg/dL = 0.79%Level 97.39 mg/dL = 0.62%Total % CV:Level 35.85 mg/dL = 2.88%Level 47.07 mg/dL = 3.52%Level 80.16 mg/dL = 2.69%Level 80.35 mg/dL = 3.06%</td></tr><tr><td colspan="1" rowspan="1">MethodComparison with</td><td colspan="1" rowspan="1">y=1.09x-2.5 mg/dL$^{0.973</td><td colspan="1" rowspan="1">y=0.91x+1.98 mg/dLr{2}=0.9768</td></tr><tr><td colspan="1" rowspan="1">Predicate</td><td colspan="1" rowspan="1">range: 5 - 105 mg/dL</td><td colspan="1" rowspan="1">range: 5.4 - 151.9 mg/dL</td></tr><tr><td colspan="1" rowspan="2">Limitations</td><td colspan="1" rowspan="1">No Significant Interference From:</td><td colspan="1" rowspan="2">No Significant Interference From:Total bilirubin (&lt;11.7 mg/dL)Direct Bilirubin (&lt;28.1 mg/dL)Hemoglobin (&lt;479 mg/dL)Triglycerides (&lt;612.5 mg/dL)</td></tr><tr><td colspan="1" rowspan="1">Unconjugated bilirubin (&lt;30mg/dL)Conjugated bilirubin (&lt;29.5mg/dL)Hemoglobin (&lt;500 mg/dL)Turbidity: Negative bias from439 mg/dL triglyceridesequivalent</td></tr><tr><td colspan="1" rowspan="1">On-BoardStability</td><td colspan="1" rowspan="1">Refrigerated Area: 28 days</td><td colspan="1" rowspan="1">Refrigerated Area: 31 days</td></tr></table>

<table><tr><td rowspan=1 colspan=1>Items</td><td rowspan=1 colspan=1>ELITech Clinical SystemsCHOLESTEROL HDL 2GCALIBRATOR(Candidate Device)</td><td rowspan=1 colspan=1>Genzyme Ultra N-Geneous CHOLESTEROLHDL Calibrator(Predicate Device)</td></tr><tr><td rowspan=1 colspan=3>Similarity</td></tr><tr><td rowspan=1 colspan=1>Intended Use</td><td rowspan=1 colspan=1>Same</td><td rowspan=1 colspan=1>For the calibration of the associated HDLCholesterol assay</td></tr><tr><td rowspan=1 colspan=1>Format</td><td rowspan=1 colspan=1>Same</td><td rowspan=1 colspan=1>Lyophilized calibrator based on human serumcontaining various lipoproteins including highdensity lipoprotein  contains sodium azide as apreservative</td></tr><tr><td rowspan=1 colspan=1>Level</td><td rowspan=1 colspan=1>Same</td><td rowspan=1 colspan=1>Single level</td></tr><tr><td rowspan=1 colspan=1>Handling</td><td rowspan=1 colspan=1>Same</td><td rowspan=1 colspan=1>Carefully open the vial to avoid loss oflyophilizate, and reconstitute with 1 mLdeionized water. Allow the closed vial to sitfor 20 minutes, and swirl gently to avoidformation of foam. Do not shake.</td></tr><tr><td rowspan=1 colspan=1>Stability</td><td rowspan=1 colspan=1>Same</td><td rowspan=1 colspan=1>Lyophilized:Store at 2-8°C protected from light until expirydatePost-Reconstitution:14 days at 2-8 °C4 weeks at &lt;80 °C (freeze only once)</td></tr></table>

<table><tr><td colspan="1" rowspan="1">Items</td><td colspan="1" rowspan="1">ELITech Clinical SystemsCHOLESTEROL LDL SL 2G(Candidate Device)</td><td colspan="1" rowspan="1">ABX PENTRA LDL Direct CP(Predicate Device)</td></tr><tr><td colspan="3" rowspan="1">Similarity</td></tr><tr><td colspan="1" rowspan="1">Intended Use</td><td colspan="1" rowspan="1">Same</td><td colspan="1" rowspan="1">For the in vitro determination of Low DensityLipoprotein Cholesterol (LDL-C) in humanserum or plasma by colorimetry.</td></tr><tr><td colspan="1" rowspan="1">Test Principle</td><td colspan="1" rowspan="1">Same</td><td colspan="1" rowspan="1">Enzymatic colorimetric test using selectivedetergent</td></tr><tr><td colspan="1" rowspan="1">ReagentComposition</td><td colspan="1" rowspan="1">Same</td><td colspan="1" rowspan="1">Reagent R1:MES BufferDetergent 1</td></tr><tr><td colspan="1" rowspan="1">b</td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1">Cholesterol EsteraseCholesterol OxidasePeroxidase4-Amino-AntipyrineAscorbate OxidasePreservativeReagent R2:MES BufferDetergent 2N,N-bis(4-sulphobutyl)-m-toluidine-disodiumPreservative</td></tr><tr><td colspan="1" rowspan="1">Reagent Form</td><td colspan="1" rowspan="1">Same</td><td colspan="1" rowspan="1">Liquid  ready to use</td></tr><tr><td colspan="1" rowspan="1">Sample Type</td><td colspan="1" rowspan="1">Same</td><td colspan="1" rowspan="1">Serum and Li-Heparin Plasma</td></tr><tr><td colspan="1" rowspan="1">Reagent Storage</td><td colspan="1" rowspan="1">Same</td><td colspan="1" rowspan="1">2-8°C away from light until expiration date</td></tr><tr><td colspan="1" rowspan="1">Expected Values</td><td colspan="1" rowspan="1">Same</td><td colspan="1" rowspan="1">According to NCEP Risk Classifications:Optimal: &lt; 100 mg/dLNear Optimal: 100-129 mg/dLBorderline High: 130-159 mg/dLHigh: 160-189 mg/dLVery High: ≥190 mg/dL</td></tr><tr><td colspan="3" rowspan="1">Difference</td></tr><tr><td colspan="1" rowspan="1">Instrument</td><td colspan="1" rowspan="1">SELECTRA JUNIOR</td><td colspan="1" rowspan="1">ABX PENTRA 400</td></tr><tr><td colspan="1" rowspan="1">MeasuringRange</td><td colspan="1" rowspan="1">15 - 380 mg/dL</td><td colspan="1" rowspan="1">1.35 - 369.39 mg/dL</td></tr><tr><td colspan="1" rowspan="1">Limit ofDetection</td><td colspan="1" rowspan="1">0.3 mg/dL</td><td colspan="1" rowspan="2">1.55 mg.dL</td></tr><tr><td colspan="1" rowspan="1">Limit ofQuantitation</td><td colspan="1" rowspan="1">10.0 mg/dL</td></tr><tr><td colspan="1" rowspan="1">Precision</td><td colspan="1" rowspan="1">Within-run % CV:Level 108 mg/dL = 1.4%Level 122 mg/dL = 1.3%Level 162 mg/dL = 2.0%Total % CV:Level 108 mg/dL = 2.6%Level 122 mg/dL = 2.7%Level 162 mg/dL = 4.0%</td><td colspan="1" rowspan="1">Within-run % CV:Level 61.26 mg/dL = 1.01%Level 75.08 mg/dL = 2.82%Level 111.26 mg/dL = 0.91%Level 141.16 mg/dL = 1.00%Level 191.16 mg/dL = 0.63%Total % CV:Level 60.64 mg/dL = 5.59%Level 74.27 mg/dL = 6.39%Level 156.58 mg/dL = 3.94%Level 191.62 mg/dL = 4.04%</td></tr><tr><td colspan="1" rowspan="1">MethodComparison withPredicate</td><td colspan="1" rowspan="1">y=0.999x0.5 mg/dLr2=0.993range: 16 - 378 mg/dL</td><td colspan="1" rowspan="1">y=0.96x0.21 mg/dLr²2=0.9963range: 1.35 - 369.39 mg/dL</td></tr><tr><td colspan="1" rowspan="1">Limitations</td><td colspan="1" rowspan="1">No Significant Interference From:Unconjugated bilirubin (&lt;30mg/dL)Conjugated bilirubin (&lt;29.5mg/dL)Hemoglobin (&lt;500 mg/dL)Turbidity: Negative bias from614 mg/dL triglyceridesequivalent</td><td colspan="1" rowspan="1">No Significant Interference From:Total bilirubin (&lt;8.19 mg/dL)Direct Bilirubin (&lt;5.63 mg/dL)Hemoglobin (&lt;460 mg/dL)Triglycerides (&lt;613 mg/dL)</td></tr><tr><td colspan="1" rowspan="1">Calibration</td><td colspan="1" rowspan="1">28 days</td><td colspan="1" rowspan="1">14 days</td></tr><tr><td colspan="1" rowspan="1">Frequency</td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1">EY</td></tr><tr><td colspan="1" rowspan="1">On-BoardStability</td><td colspan="1" rowspan="1">Refrigerated Area: 28 days</td><td colspan="1" rowspan="1">Refrigerated Area: 97 days</td></tr></table>

<table><tr><td rowspan=1 colspan=1>Items</td><td rowspan=1 colspan=1>ELITech Clinical SystemsCHOLESTEROL LDL 2GCALIBRATOR(Candidate Device)</td><td rowspan=1 colspan=1>Genzyme Ultra N-Geneous CHOLESTEROLLDL Calibrator(Predicate Device)</td></tr><tr><td rowspan=1 colspan=3>Similarity</td></tr><tr><td rowspan=1 colspan=1>Intended Use</td><td rowspan=1 colspan=1>Same</td><td rowspan=1 colspan=1>For the calibration of the associated LDLCholesterol assay</td></tr><tr><td rowspan=1 colspan=1>Format</td><td rowspan=1 colspan=1>Same</td><td rowspan=1 colspan=1>Lyophilized calibrator based on human serumcontaining various lipoproteins including lowdensity lipoprotein  contains sodium azide as apreservative</td></tr><tr><td rowspan=1 colspan=1>Level</td><td rowspan=1 colspan=1>Same</td><td rowspan=1 colspan=1>Single level</td></tr><tr><td rowspan=1 colspan=1>Handling</td><td rowspan=1 colspan=1>Same</td><td rowspan=1 colspan=1>Carefully open the vial to avoid loss oflyophilizate, and reconstitute with 1 mLdeionized water. Allow the closed vial to sitfor 5 minutes, and swirl gently to avoidformation of foam. Do not shake.</td></tr><tr><td rowspan=1 colspan=1>Stability</td><td rowspan=1 colspan=1>Same</td><td rowspan=1 colspan=1>Lyophilized:Store at 2-8°C protected from light until expirydatePost-Reconstitution:14 days at 2-8 °C4 weeks at &lt;80 °C (freeze only once)</td></tr></table>

<table><tr><td colspan="1" rowspan="1">Items</td><td colspan="1" rowspan="1">ELITech Clinical SystemsELITROL I and ELITROL II(Candidate Device)</td><td colspan="1" rowspan="1">Roche Precinorm U / Precipath U(Predicate Device)</td></tr><tr><td colspan="3" rowspan="1">Similarity</td></tr><tr><td colspan="1" rowspan="1">Intended Use</td><td colspan="1" rowspan="1">Same</td><td colspan="1" rowspan="1">For the in vitro diagnostic use in the qualitycontrol for the quantitative determination ofHDL and LDL Cholesterol by the respectivemethod.</td></tr><tr><td colspan="1" rowspan="1">Format</td><td colspan="1" rowspan="1">Same</td><td colspan="1" rowspan="1">Lyophilized human sera with constituentsadded as required to obtain desired componentlevels</td></tr><tr><td colspan="1" rowspan="1">Levels</td><td colspan="1" rowspan="1">Same</td><td colspan="1" rowspan="1">Two levels</td></tr><tr><td colspan="1" rowspan="1">Handling</td><td colspan="1" rowspan="1">Same</td><td colspan="1" rowspan="1">Carefully open the vial to avoid loss oflyophilizate, and reconstitute with 5 mLdeionized water. Dissolve lyophilizate withoccasional gentle swirling for 30 minutes, andavoid the formation of foam.</td></tr><tr><td colspan="1" rowspan="1">Stability</td><td colspan="1" rowspan="1">Same</td><td colspan="1" rowspan="1">Lyophilized:Store at 2-8°C protected from light until expirydatePost-Reconstitution:</td></tr><tr><td></td><td></td><td>12 hours at 15-25 °C 5 days at 2-8 °C 4 weeks at -25 to -15 °C (freeze only once)</td></tr></table>

# K. Standard/Guidance Document Referenced (if applicable):

CLSI Guideline EP05-A2: Evaluation of Precision Performance of Qualitative   
Measurement Methods   
CLSI Guideline EP06-A: Evaluation of the Linearity of Qualitative Measurement   
Methods   
CLSI Guideline EP07-A2: Interference Testing in Clinical Chemistry   
CLSI Guideline EP09-A2: Method Comparison and Bias Estimation Using Patient   
Samples   
CLSI Guideline EP17-A: Protocols for Determination of Limits of Detection and Limits   
of Quantitation   
CEN 13640: Stability Testing of In Vitro Diagnostic Reagents

# L. Test Principle:

# ELITech Clinical Systems CHOLESTEROL HDL SL 2G:

An enzymatic colorimetric determination of HDL cholesterol based on accelerator selective detergent. First, the patient sample is mixed with reagent R1 containing a selective accelerator to deactivate all cholesterol of non-HDL lipoproteins (LDL, VLDL & chylomicrons):

LDL, VLDL, Chylomicron

Non-reactive LDL, VLDL, Chylomicron

Second, reagent R2 is added to solubilize and enzymatically measure HDL via a color formation with peroxidase:

![](images/91d87e566ee5ea0a19d1c19bd2ca1453282ba43f8e9815d5faabb7591b40ca6b.jpg)

# ELITech Clinical Systems CHOLESTEROL LDL SL 2G:

An enzymatic colorimetric determination of LDL cholesterol based on selective detergent.

First, the sample is mixed with reagent R1 to solubilize non-LDL lipoproteins and eliminate released cholesterol:

Cholesterol, HDL, VLDL, Chylomicron

Colorless products

Second, reagent R2 is added to solubilize LDL and measure it by color formation:

![](images/1f65f560aa628becaa360c79cf2e711c52b1f833af4613defa62c6489977891e.jpg)

# M. Performance Characteristics (if/when applicable):

1. Analytical performance:

a. Precision/Reproducibility:

ELITech Clinical Systems CHOLESTEROL HDL SL 2G:

Precision was evaluated following guideline EP5-A2. Two replicates each of 3 control samples at clinically relevant decision levels were tested twice a day on 20 separate days, yielding 80 replicates total over 40 runs. Control samples included one diluted (all dilutions for performance testing was done with saline) human sera pool sample, one human sera pool sample, and one spiked human sera pool sample. The results are presented in the table below:

Precision Results:   

<table><tr><td rowspan="2"></td><td colspan="6">Units = mg/dL</td><td rowspan="2">No. No. Days</td></tr><tr><td>Mean</td><td>Within-run</td><td></td><td>Between-day</td><td>Total</td><td></td></tr><tr><td>Sample</td><td>HDL</td><td>SD</td><td>CV (%)</td><td>SD CV (%)</td><td>SD</td><td>CV (%)</td><td>Observ. 80</td></tr><tr><td>Low Sample</td><td>31</td><td>0.4</td><td>1.4%</td><td>0.7 2.3%</td><td>0.9</td><td>3.0%</td><td>20</td></tr><tr><td>Medium Sample</td><td>56</td><td>0.4</td><td>0.7% 1.1</td><td>2.0%</td><td>1.6</td><td>2.8% 80</td><td>20</td></tr><tr><td>High Sample</td><td>87</td><td>1.2</td><td>1.4% 1.6</td><td>1.8%</td><td>2.8</td><td>3.3% 80</td><td>20</td></tr></table>

# ELITech Clinical Systems CHOLESTEROL LDL SL 2G:

Precision was evaluated following guideline EP5-A2. Two replicates each of 3 control samples at clinically relevant decision levels were tested twice a day on 20 separate days, yielding 80 replicates total over 40 runs. Control samples included one low sample of liquicheck lipid 1, one normal human sera pool sample, and one spiked human sera pool sample. The results are presented in the table below:

Precision Results:   

<table><tr><td rowspan="2"></td><td colspan="6">Units = mg/dL</td><td rowspan="2">No. No. Observ.</td></tr><tr><td>Mean</td><td>Within-run</td><td></td><td>Between-day</td><td>Total</td><td></td></tr><tr><td>Sample</td><td>HDL</td><td>SD</td><td>CV (%) SD</td><td>CV (%)</td><td>SD</td><td>CV (%)</td><td>Days</td></tr><tr><td>Low Sample</td><td>108</td><td>1.5 1.4%</td><td>1.6</td><td>1.4%</td><td>2.8</td><td>2.6% 80</td><td>20</td></tr><tr><td>Medium Sample</td><td>122</td><td>1.5 1.3%</td><td>1.7</td><td>1.4%</td><td>3.2 2.7%</td><td>80</td><td>20</td></tr><tr><td>High Sample</td><td>162</td><td>3.2 2.0%</td><td>0.0</td><td>0.0%</td><td>6.4</td><td>4.0% 80</td><td>20</td></tr></table>

# b. Linearity/assay reportable range:

ELITech Clinical Systems CHOLESTEROL HDL SL 2G:

Study Protocol:

Linearity was evaluated following CLSI guideline EP6-A. Serum pools were used for the studies. High spiked pool samples were diluted using low pool samples (serum diluted with saline) to give a total of 8 sample dilutions, ranging from $5 \mathrm { m g / d L }$ to $1 1 0 \mathrm { m g / d L }$ . Statistical evaluation gave the following results:

Serum Linearity Study: $\mathrm { y } = \ 1 . 0 5 \mathrm { x } - 2$ $\mathrm { r } = 0 . 9 9 8 9$

Based on the linearity results, the sponsor claimed that the assay is linear from $5 \mathrm { m g / d L }$ to $1 0 5 \mathrm { m g / d L }$ .

ELITech Clinical Systems CHOLESTEROL LDL SL 2G:

Study Protocol:

Linearity was evaluated following CLSI guideline EP6-A. Serum pools were used for the studies. High spiked pool samples were diluted using low pool samples (serum diluted with saline) to give a total of 11 sample dilutions, ranging from $1 5 \mathrm { m g / d L }$ to $3 8 0 \mathrm { m g / d L }$ . Statistical evaluation gave the following results:

Serum Linearity Study: $\mathbf { y } = \mathbf { \varepsilon } _ { 1 . 0 3 } \mathbf { 1 x } - \boldsymbol { 5 }$ $\mathrm { r } = 0 . 9 9 9 4$

Based on the linearity results, the sponsor claimed that the assay is linear from $1 5 \mathrm { m g / d L }$ to $3 8 0 \mathrm { m g / d L }$ .

c. Traceability, Stability, Expected values (controls, calibrators, or methods):

# Traceability:

The ELITech Clinical Systems CHOLESTEROL HDL 2G CALIBRATOR, the ELITech Clinical Systems CHOLESTEROL LDL 2G CALIBRATOR, and the ELITech Clinical Systems ELITROL I and ELITROL II are traceable to the reference method recommended by the CDC. These calibrators are all reviewed under 510(k) numbers k021316, k971573, and k093883 respectively.

# Stability:

Real-time testing as well as on-board, shelf life and post-reconstitution stability studies were conducted. The stability study protocols and the sponsor defined acceptance criteria have been reviewed and found to be acceptable. The study results support the stability claims summarized in the below table.

Stability Results:   

<table><tr><td rowspan=1 colspan=1>Item</td><td rowspan=1 colspan=2>Storage Conditions</td><td rowspan=1 colspan=1>ClaimedStability</td></tr><tr><td rowspan=2 colspan=1>HDLReagentPacks</td><td rowspan=1 colspan=1>Close-Vial</td><td rowspan=1 colspan=1>2-8</td><td rowspan=1 colspan=1>24 months</td></tr><tr><td rowspan=1 colspan=1>Open-Vial</td><td rowspan=1 colspan=1>On system</td><td rowspan=1 colspan=1>28 days</td></tr><tr><td rowspan=3 colspan=1>HDLCalibrator</td><td rowspan=1 colspan=1>Close-Vial</td><td rowspan=1 colspan=1>2-8C</td><td rowspan=1 colspan=1>24 months</td></tr><tr><td rowspan=1 colspan=1>Open-Reconstituted</td><td rowspan=1 colspan=1>2-8</td><td rowspan=1 colspan=1>14 days</td></tr><tr><td rowspan=1 colspan=1>Open-Reconstituted</td><td rowspan=1 colspan=1>≤-80</td><td rowspan=1 colspan=1>4 weeks</td></tr><tr><td rowspan=2 colspan=1>LDLReagentPacks</td><td rowspan=1 colspan=1>Close-Vial</td><td rowspan=1 colspan=1>2-8°</td><td rowspan=1 colspan=1>24 months</td></tr><tr><td rowspan=1 colspan=1>Open-Vial</td><td rowspan=1 colspan=1>On system</td><td rowspan=1 colspan=1>28 days</td></tr><tr><td rowspan=3 colspan=1>LDLCalibrator</td><td rowspan=1 colspan=1>Close-Vial</td><td rowspan=1 colspan=1>2-8°C</td><td rowspan=1 colspan=1>24 months</td></tr><tr><td rowspan=1 colspan=1>Open-Reconstituted</td><td rowspan=1 colspan=1>2-8°</td><td rowspan=1 colspan=1>14 days</td></tr><tr><td rowspan=1 colspan=1>Open-Reconstituted</td><td rowspan=1 colspan=1>≤ -80°</td><td rowspan=1 colspan=1>4 weeks</td></tr><tr><td rowspan=3 colspan=1>Controls</td><td rowspan=1 colspan=1>Close-Vial</td><td rowspan=1 colspan=1>2-8°C</td><td rowspan=1 colspan=1>24 months</td></tr><tr><td rowspan=1 colspan=1>Open-Reconstituted</td><td rowspan=1 colspan=1>15-25°C</td><td rowspan=1 colspan=1>12 hours</td></tr><tr><td rowspan=1 colspan=1>Open-Reconstituted</td><td rowspan=1 colspan=1>2-8</td><td rowspan=1 colspan=1>5 days</td></tr><tr><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1>Open-Reconstituted</td><td rowspan=1 colspan=1>-25 to-15C</td><td rowspan=1 colspan=1>4 weeks</td></tr></table>

# Calibration Interval:

ELITech Clinical Systems CHOLESTEROL HDL 2G and LDL 2G CALIBRATORS:

Stability across a 28 day calibration interval was assessed by calculating the percentage bias of the precision samples on each day from the result obtained for that precision

samples from the calibration on the first day. The results support the product claim of a 28- day calibration interval.

# Value Assignment:

ELITech Clinical Systems CHOLESTEROL HDL 2G and LDL 2G CALIBRATORs:

Value assignment of all calibrators is obtained by assaying the new calibrator sets as unknowns, run in triplicate on one machine. The mean is calculated based upon comparison with an already approved calibrator lot. Acceptance criteria state that the new calibrators must fall within $\pm 1 0 \%$ of the target values.

ELITech Clinical Systems ELITROL I and ELITROL II

Value assignment of controls is obtained by assaying 3 vials of reconstituted controls of the same lot, run in triplicate on one machine. The mean is calculated and compared to the certificate of analysis from the manufacturing company. Acceptance criteria state that the controls must fall within $\pm 1 5 \%$ of the target values listed in the certificate of analysis.

The ELITech Clinical Systems CHOLESTEROL HDL SL 2G and CHOLESTEROL LDL SL 2G assays have not been tested or certified by the Cholesterol Reference Method Laboratory Network (CRMLN).

# d. Detection limit:

Limit of Blank (LoB), Limit of Detection (LoD) and Limit of Quantitation (LoQ) were determined following guideline EP17-A.

ELITech Clinical Systems CHOLESTEROL HDL SL 2G:

# Study Protocol:

For LoB determination, 60 replicates of blank samples were measured on one day, using one analyzer and one reagent lot – giving 60 determinations in total.

For LoD determination, four diluted sample pools were prepared from four different patient samples pools and diluted with saline to obtain a concentration close to four times the calculated LoB. Each of the sample pools was measured 15 times in one run, using one instrument and one reagent lot. As the resultant data was not Gaussian, the LoD was calculated as $\mathrm { L o B + D _ { S , \beta } }$ (where $\mathrm { D } _ { \mathrm { S } , \beta }$ is determined by calculating the median minus the $5 ^ { \mathrm { t h } }$ percentile in the low concentration sample distribution).

For LoQ determination, four sample pools were prepared from four different patient samples pools and diluted with saline to obtain a concentration close to the expected LoQ. Each of the sample pools was measured 15 times in one run, using one instrument and

one reagent lot. By calculating the total error interval $( = \mathrm { B i a s } \pm 2 \mathrm { S D } )$ with a sponsor defined acceptance criterion of $\leq 1 5 . 8 \%$ total error, the LoQ was determined and was acceptable.

# Result Summary HDL:

Based on the study result, the following detection limit claims were made:

<table><tr><td rowspan=1 colspan=1>LoB</td><td rowspan=1 colspan=1>LoD</td><td rowspan=1 colspan=1>LoQ</td></tr><tr><td rowspan=1 colspan=1>0.3 mg/dL</td><td rowspan=1 colspan=1>0.7 mg/dL</td><td rowspan=1 colspan=1>5 mg/dL</td></tr></table>

# ELITech Clinical Systems CHOLESTEROL LDL SL 2G:

# Study Protocol:

For LoB determination, 60 replicates of blank samples were measured on one day, using one analyzer and one reagent lot – giving 60 determinations in total.

For LoD determination, four diluted sample pools were prepared from four different patient samples pools and diluted with saline to obtain a concentration close to four times the calculated LoB. Each of the sample pools was measured 15 times in one run, using one instrument and one reagent lot. As the resultant data was not Gaussian, the LoD was calculated as $\mathrm { L o B + D _ { S , \beta } }$ (where $\mathrm { D } _ { \mathrm { S } , \beta }$ is determined by calculating the median minus the $5 ^ { \mathrm { t h } }$ percentile in the low concentration sample distribution).

For LoQ determination, four sample pools were prepared from four different patient samples pools and diluted with saline to obtain a concentration close to the expected LoQ. Each of the sample pools was measured 15 times in one run, using one instrument and one reagent lot. By calculating the total error interval $( = \mathrm { B i a s } \pm 2 \mathrm { S D } )$ with a sponsor defined acceptance criterion of $\leq 1 2 \%$ total error, the LoQ was determined and was acceptable.

# Result Summary LDL:

Based on the study result, the following detection limit claims were made:

<table><tr><td rowspan=1 colspan=1>LoB</td><td rowspan=1 colspan=1>LoD</td><td rowspan=1 colspan=1>LoQ</td></tr><tr><td rowspan=1 colspan=1>0.1 mg/dL</td><td rowspan=1 colspan=1>0.3 mg/dL</td><td rowspan=1 colspan=1>10 mg/dL</td></tr></table>

e. Analytical specificity:

Interference

# ELITech Clinical Systems CHOLESTEROL HDL SL 2G:

# Study Protocol:

The sponsor evaluated the effect of the interfering substances using two patient serum pools with endogenous HDL at $3 1 \mathrm { m g / d L }$ and $5 4 \mathrm { m g / d L }$ . For each potential interfering substance, between 5 and 9 different concentrations were spiked with the test substance up to the maximum level shown below. The sponsor defined no significant interference $\mathrm { a s } \pm \le 1 0 \%$ . The HDL results (mean of triplicates) of the paired pools were compared and $\%$ difference was calculated and evaluated for interference determination.

# Result Summary:

Based on the sponsor-defined interference limit of $\pm 1 0 \%$ , the following claims were made:

The below compounds at the indicated concentration do not cause significant interference with the assay.

<table><tr><td rowspan=1 colspan=1>Compound</td><td rowspan=1 colspan=1>Concentration up to</td></tr><tr><td rowspan=1 colspan=1>Bilirubin (unconjugated)</td><td rowspan=1 colspan=1>30 mg/dL</td></tr><tr><td rowspan=1 colspan=1>Bilirubin (conjugated)</td><td rowspan=1 colspan=1>29.5 mg/dL</td></tr><tr><td rowspan=1 colspan=1>Hemoglobin</td><td rowspan=1 colspan=1>500 mg/dL</td></tr><tr><td rowspan=1 colspan=1>Triglycerides (Intralipid)</td><td rowspan=1 colspan=1>439 mg/dL</td></tr></table>

# ELITech Clinical Systems CHOLESTEROL LDL SL 2G:

# Study Protocol:

The sponsor evaluated the effect of the interfering substances using two patient serum pools with endogenous LDL at $1 0 0 \mathrm { m g / d L }$ and $1 6 0 \mathrm { m g / d L }$ . For each potential interfering substance, between 5 and 9 different concentrations were spiked with the test substance up to the maximum level shown below. The sponsor defined no significant interference $\mathrm { a s } \pm \le 1 0 \%$ . The LDL results (mean of triplicates) of the paired pools were compared and $\%$ difference was calculated and evaluated for interference determination.

# Result Summary:

Based on the sponsor-defined interference limit of $\pm 1 0 \%$ , the following claims were made:

The below compounds at the indicated concentration do not cause significant interference with the assay.

<table><tr><td rowspan=1 colspan=1>Compound</td><td rowspan=1 colspan=1>Concentration up to</td></tr><tr><td rowspan=1 colspan=1>Bilirubin (unconjugated)</td><td rowspan=1 colspan=1>30 mg/dL</td></tr><tr><td rowspan=1 colspan=1>Bilirubin (conjugated)</td><td rowspan=1 colspan=1>29.5 mg/dL</td></tr><tr><td rowspan=1 colspan=1>Hemoglobin</td><td rowspan=1 colspan=1>500 mg/dL</td></tr><tr><td rowspan=1 colspan=1>Triglycerides (Intralipid)</td><td rowspan=1 colspan=1>614 mg/dL</td></tr><tr><td rowspan=1 colspan=1>Ascorbic Acid</td><td rowspan=1 colspan=1>20 mg/dL</td></tr></table>

The package insert for each the HDL and LDL assays contains a statement that other compounds may interfere and users should refer to the following literature references:

o Young, D. S., Effects of preanalytical variables on clinical laboratory tests, $2 ^ { \mathrm { n d } }$ Ed., AACC Press, (1997).   
o Young, D.S., Effects of drugs on clinical laboratory tests, $4 ^ { \mathrm { t h } }$ Ed., AACC Press, (1995).   
o Berth, M. & Delanghe, J. Protein precipitation as a possible important pitfall in the clinical chemistry analysis of blood samples containing monoclonal

immunoglobulins: 2 case reports and a review of literature, Acta Clin Belg., (2004), 59, 263.

f. Assay cut-off:

Not applicable.

2. Comparison studies:

a. Method comparison with predicate device:

ELITech Clinical Systems CHOLESTEROL HDL SL 2G:

Study Protocol:

A total of 88 patient serum samples (3 spiked) from an independent clinical laboratory and a hospital laboratory were used in the method comparison studies. Samples were assayed in duplicate and ranged from $5 \mathrm { m g / d L }$ to $9 4 ~ \mathrm { m g / d L }$

# Result Summary:

Linear Regression analysis yielded the equation $\mathrm { y } = 1 . 0 9 \mathrm { x } - 2 . 5$ , with an r value of 0.986.

ELITech Clinical Systems CHOLESTEROL LDL SL 2G:

# Study Protocol:

A total of 100 patient serum samples (7 spiked and 3 diluted) from an independent clinical laboratory and a hospital laboratory were used in the method comparison studies. Samples were assayed in duplicate and ranged from $1 6 \mathrm { m g / d L }$ to $3 7 8 \mathrm { m g / d L }$ . Regression analysis was performed between the candidate system and the predicate ABX Pentra system.

# Result Summary:

Linear Regression analysis yielded the equation $\mathrm { y } = 0 . 9 9 9 \mathrm { x } - 0 . 5$ , with an r value of 0.997.

b. Matrix comparison:

ELITech Clinical Systems CHOLESTEROL HDL SL 2G:

# Study Protocol:

The matrix effect on serum and Li-Heparin plasma samples was evaluated. 32 matched patient samples were enrolled in the study. To cover the entire measuring range of the assay, three of the samples were spiked and one sample was diluted. Samples ranged from 6 to $9 4 ~ \mathrm { m g / d L }$ . Differences in HDL values (mean of duplicate determinations) between serum and plasma was evaluated using a Bias plot and correlation graph.

Result Summary: Linear Regression analysis yielded the equation $\mathrm { y } = 0 . 9 5 2 \mathrm { x } + 0 . 7 4$ , with an r value of 0.990.

ELITech Clinical Systems CHOLESTEROL LDL SL 2G:

# Study Protocol:

The matrix effect on serum and Li-Heparin plasma samples was evaluated. 40 matched patient samples were enrolled in the study. To cover the entire measuring range of the assay, three of the samples were spiked and one sample was diluted. Samples ranged from 15 to $3 6 5 \mathrm { m g / d L }$ . Differences in LDL values (mean of duplicate determinations) between serum and plasma was evaluated using a Bias plot and correlation graph.

Result Summary: Linear Regression analysis yielded the equation $\mathbf { y } = 0 . 9 8 7 \mathbf { x } - 2$ , with an r value of 0.997.

3. Clinical studies:

a. Clinical Sensitivity: Not applicable

b. Clinical specificity: Not applicable

c. Other clinical supportive data (when a. and b. are not applicable): Not applicable

4. Clinical cut-off: Not applicable

5. Expected values/Reference range: ELITech Clinical Systems CHOLESTEROL HDL SL 2G:

The reference intervals listed were taken from literature\*.

<table><tr><td rowspan=1 colspan=1>Cardiovascular Risk</td><td rowspan=1 colspan=1>Conventional units</td><td rowspan=1 colspan=1>S.I. units</td></tr><tr><td rowspan=1 colspan=1>Low</td><td rowspan=1 colspan=1>≥ 60 mg/dL</td><td rowspan=1 colspan=1>≥ 1.55 mmol/L</td></tr><tr><td rowspan=1 colspan=1>High</td><td rowspan=1 colspan=1>&lt; 40 mg/dL</td><td rowspan=1 colspan=1>&lt; 1.03mmol/L</td></tr></table>

\*Expert Panel on Detection, Evaluation and Treatment of High Cholesterol in Adults (Adult Treatment Panel III), May (2001).

NIH Publication No. 01 3305, ATP III Guidelines At-A-Glance, Quick Desk Reference, May (2001).   
NIH Publication No. 01 3670, Third Report of National Cholesterol Education Program (NCEP).

The package insert includes precautionary language that each laboratory should establish its own reference intervals based upon its patient population.

# ELITech Clinical Systems CHOLESTEROL LDL SL 2G:

The reference intervals listed were taken from literature\*.

<table><tr><td rowspan=1 colspan=1>Classification</td><td rowspan=1 colspan=1>Conventional units</td><td rowspan=1 colspan=1>S.I. units</td></tr><tr><td rowspan=1 colspan=1>Optimal</td><td rowspan=1 colspan=1>&lt; 100 mg/dL</td><td rowspan=1 colspan=1>&lt; 1.00 mmol/L</td></tr><tr><td rowspan=1 colspan=1>Near Optimal</td><td rowspan=1 colspan=1>100-129mg/dL</td><td rowspan=1 colspan=1>1.00 - 1.29mmol/L</td></tr><tr><td rowspan=1 colspan=1>Borderline High</td><td rowspan=1 colspan=1>130159mg/dL</td><td rowspan=1 colspan=1>1.30- 1.59mmol/L</td></tr><tr><td rowspan=1 colspan=1>High</td><td rowspan=1 colspan=1>160- 189mg/dL</td><td rowspan=1 colspan=1>1.60 - 1.89mmol/L</td></tr><tr><td rowspan=1 colspan=1>Very High</td><td rowspan=1 colspan=1>≥ 190 mg/dL</td><td rowspan=1 colspan=1>≥ 4.91mmol/L</td></tr></table>

\*The reference Interval for LDLC is based on the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III); Executive Summary. NIH Publication No. 01- 3670, National Institutes of Health. Bethesda. Maryland: May 2001.

The package insert includes precautionary language that each laboratory should establish its own reference intervals based upon its patient population.

# N. Proposed Labeling:

The labeling is sufficient and it satisfies the requirements of 21 CFR Part 809.10.

# O. Conclusion:

The submitted information in this premarket notification is complete and supports a substantial equivalence decision.